Objective: To compare the efficacy of topical minoxidil and platelet-rich plasma (PRP) in the treatment of alopecia areata (AA).
Study Design: Randomised control trial. Place and Duration of the Study: Department of Dermatology, Jinnah Postgraduate Medical Centre, Karachi, Pakistan, from December 2021 to June 2022.
Methodology: The study included all the patients who visited JPMC Karachi during the study period. Permission from the ERB was obtained. The inclusion criteria were any gender and age 10 to 45 years. Topical minoxidil 5% solution was applied twice daily to Group A (six pubs/time), while PRP injections were administered to Group B at baseline and every four weeks for three months. Serial photos and the severity of alopecia tool (SALT) were used to determine the clinical assessment. When comparing the effectiveness between the two groups, a p-value of <0.05 was considered significant. SPSS version 23 was used to analyse the data.
Results: Mean age was 23.11 ± 8.9 years in 376 patients. PRP and Minoxidil groups had mean SALT scores at three months that were 1.48 and 1.54, respectively. Both treatments were shown to be efficacious. There was no statistically significant difference in efficacy between the minoxidil solution and PRP (p = 0.483).
Conclusion: There is no apparent difference between PRP and topical minoxidil 5% solution in the management of AA. To verify the results, additional studies are needed with a larger sample size and a longer duration of follow-up.
Key Words: Minoxidil, Platelet-rich plasma, Alopecia areata, Severity of alopecia tool score.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.29271/jcpsp.2024.06.650 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GC1126A, a novel ADAMTS13 mutein, evades autoantibodies in immune-mediated thrombotic thrombocytopenic purpura.
Sci Rep
January 2025
Discovery3 Team, Department of Research and Early Development, GC Biopharma, 93, Ihyeon-ro 30Beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, South Korea.
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by the formation of blood clots in small blood vessels. It is caused by antibodies targeting the A disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13), which plays a role in cleaving von Willebrand factor. Most patients with iTTP have autoantibodies against specific domains of the ADAMTS13 protein, particularly the cysteine-rich and spacer domains.
View Article and Find Full Text PDFInvited Response on: Comment on ''The Impact of Duration and Force of Centrifugation on Platelet Content and Mass in the Preparation of Platelet-Rich Plasma''.
Aesthetic Plast Surg
January 2025
Plastic, Reconstructive and Aesthetic Surgery Clinic, Istanbul Demiroglu Bilim University, 34384, Istanbul, Turkey.
Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.
View Article and Find Full Text PDFPlatelet-Rich Plasma in the Treatment of Diabetic Foot Ulcers.
Adv Skin Wound Care
January 2025
At Mayo Clinic, Rochester, Minnesota, United States, Paul T. Gomez, BS, is Summer Research Fellow, Regenerative Sciences Track, Mayo Clinic Graduate School of Biomedical Sciences; Saranya P. Wyles, MD, PhD, is Consultant, Department of Dermatology; and Karen L. Andrews, MD, is Director, Vascular Ulcer and Wound Healing Clinic/Gonda Vascular Center, and Consultant, Department of Physical Medicine and Rehabilitation. At Mayo Clinic, Jacksonville, Florida, Jennifer R. Arthurs is APRN, Center for Regenerative Medicine; and Alison J. Bruce, MB, ChB, is Consultant, Department of Dermatology.
Background: Chronic nonhealing neuropathic foot ulcers affect approximately 15% to 30% of patients with diabetes mellitus and are associated with significant morbidity and mortality. Although current strategies to address these chronic wounds include a multifactorial approach, clinical outcomes remain poor and warrant improvement. Platelet-rich plasma (PRP), derived from autologous or allogeneic blood, is an emerging regenerative product that aims to serve as an adjuvant to standard diabetic foot ulcer (DFU) treatment.
View Article and Find Full Text PDFImpact of Platelet-rich Plasma and Platelet-rich Fibrin in Mandibular Third Molar Extraction: A Systematic Review.
J Contemp Dent Pract
September 2024
Department of Periodontology, Narsinhbhai Patel Dental College and Hospital, Sankalchand Patel University, Visnagar, Gujarat, India.
Aim: This study aims to evaluate the impact of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on pain, swelling, trismus, soft tissue healing and bone regeneration following mandibular third molar extraction.
Material And Methods: A systematic review was conducted from a period of January 2014 to June 2024 using PRISMA guidelines. The search strategy included databases such as Scopus, PubMed, Google Scholar, and Cochrane Central Register of Controlled Trials, using key terms related to "PRF", "PRP", oral surgery, and third molars.
The Impact of Injectable Platelet-rich Fibrin on Orthodontic Tooth Movement during Retraction: A Randomized Controlled Trial.
J Contemp Dent Pract
September 2024
Department of Orthodontics and Dentofacial Orthopedics, Chettinad Dental College & Research Institute, Chengalpet, Tamil Nadu, India.
Aim: This study intended to comprehend the effects of injectable platelet-rich fibrin (i-PRF) on anchor loss and space closure rates during the retraction phase of orthodontic treatment.
Materials And Methods: Twenty-four participants with malocclusion, necessitating extractions and space closure during orthodontic treatment, were enrolled and divided into two groups ( = 12 participants) group A: the experimental group was administered i-PRF on the maxilla/mandible, while group B: the control group did not. Measurements of the rate of space closure, anchor loss, and salivary enzyme activity were done before retraction (T0), after three weeks (T1), after six weeks (T2), and after nine weeks (T3).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!